RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC

RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC

The era of precision medicine has resulted in the identification of a number of genomic alterations that can be targeted with novel therapies. In lung adenocarcinomas, a histology structure that accounts for nearly 50% of all cases of lung cancer, and a number of genomic targets have been linked wit...

Full description

Bibliographic Details
Main Authors: Badi El Osta, MD, Suresh S. Ramalingam, MD, FACP, FASCO
Format: Article
Language:English
Published: Elsevier 2020-09-01
Series:JTO Clinical and Research Reports
Subjects:
Lung cancer
Precision oncology
Pralsetinib
RET fusion
Selpercatinib
Targeted Therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364320300552

Internet

http://www.sciencedirect.com/science/article/pii/S2666364320300552

Similar Items